Last updated: February 27, 2026
What is NDC 69230-0322?
NDC 69230-0322 is a drug identified as "Nivolumab," marketed under the brand name Opdivo. It is a PD-1 immune checkpoint inhibitor used primarily for treating melanoma, non-small cell lung cancer, renal cell carcinoma, and other cancers.
Market Size and Growth
Current Market Valuation
- The global nivolumab market stood at approximately $8.2 billion in 2022.
- Expected Compound Annual Growth Rate (CAGR): 11.4% from 2023 to 2028.
Key Drivers
- Expansion of approved indications, including lung, melanoma, and gastric cancers.
- Increasing adoption in combination therapies.
- An aging population globally increases demand for immuno-oncology therapies.
- Ongoing clinical trials exploring additional indications.
Competitive Environment
- Major competitors: pembrolizumab (Keytruda), atezolizumab (Tecentriq), and durvalumab (Imfinzi).
- Market share (2022): Opdivo approximately 35%, Keytruda at 45%, others split remaining 20%.
- Patent expirations: Several patents for Opdivo are set to expire between 2029 and 2032, potentially affecting pricing and market share.
Pricing Landscape
Current Pricing
- The average wholesale price (AWP) for a 240 mg infusion of nivolumab ranges from $12,000 to $16,000 per dose.
- List prices vary depending on indication, dosing schedule, and region.
- In the United States, the average net price after discounts and rebates is approximately $9,000 per dose.
Reimbursement Policies
- Medicare and commercial insurance often negotiate discounts.
- U.S. government programs and Medicaid have specific reimbursement agreements that reduce payer costs.
Price Projections
Short-term forecasts (2023–2025)
- Market pressures from biosimilars and patent expiries could reduce prices by 5-10% annually.
- Price reductions are likely driven by increased competition from biosimilars, expected launch dates between 2024 and 2026.
- Manufacturers may introduce value-based pricing models to maintain margins.
Long-term outlook (2026–2030)
- Stabilization of prices as biosimilars gain market share.
- Prices may decrease by an aggregate 15-25% over this period.
- New indications and combination therapies could offset some price reductions by expanding market size.
- Potential for price increases in emerging markets due to increased access and formulary placement, counteracting some Western price declines.
Influence of Biosimilars
- Biosimilar versions of nivolumab are projected to hit the market by 2024–2025.
- These are expected to initially establish at 20-30% lower prices than the originator.
- Market share could shift rapidly post-launch, reducing the originator’s pricing power.
Regulatory and Policy Impact
- Price controls in certain markets (e.g., EU, Canada) could suppress prices further.
- U.S. policy initiatives aimed at drug pricing transparency might lead to price negotiations favoring payers.
- Market access varies significantly between regions, affecting regional pricing strategies.
Key Considerations for Stakeholders
- Companies developing biosimilars should anticipate significant price erosion post-approval.
- Manufacturers of originator drugs may focus on expanding indications and personalized medicine to mitigate price pressures.
- Payers may leverage formulary strategies to negotiate discounts and control access.
Summary Table: Market and Pricing Snapshot
| Aspect |
Data/Projection |
Notes |
| 2022 Market Size |
$8.2 billion |
Global immuno-oncology market |
| CAGR (2023–2028) |
11.4% |
Driven by broader indication approvals |
| Current Price (U.S.) |
~$9,000 per dose |
Net price after discounts |
| Biosimilar Entry |
2024–2025 |
Expected 20-30% lower price points |
| Price Decline (2026–2030) |
15-25% |
Due to biosimilar competition and market dynamics |
Key Takeaways
- The nivolumab market is growing steadily, fueled by new indications and combination therapies.
- Prices are projected to decline over the next five years due to biosimilar entry and patent expiries.
- Payers and providers will influence pricing through reimbursement strategies.
- Long-term price stability will depend on market expansion and adaptation to biosimilar competition.
FAQs
Q1: When will biosimilars for nivolumab become available?
A1: Expected launch dates are between 2024 and 2025.
Q2: How much could biosimilar entry reduce prices?
A2: Prices are likely to decrease 20-30% relative to the originator.
Q3: Are there regional differences in pricing?
A3: Yes; North America generally has higher prices than Europe or emerging markets due to differing regulatory and reimbursement policies.
Q4: What are the main indications driving future growth?
A4: Lung cancer, melanoma, renal cell carcinoma, and emerging data on other solid tumors.
Q5: How are manufacturers responding to price pressure?
A5: They are pursuing indication expansion, combination therapies, and value-based pricing agreements.
References
- Markets and Markets. (2023). Immuno-oncology Market by Therapy Type, Application, and Region.
- IQVIA. (2022). Global Oncology Market Insights.
- U.S. Food and Drug Administration. (2023). Biosimilar Approval and Market Entry Timeline.
- ClinicalTrials.gov. (2023). Ongoing trials involving nivolumab combinations and new indications.
- Evaluate Pharma. (2023). Forecasting Global Cancer Immunotherapy Market.
